Therapeutic Asset Ratings
176 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
jk08
Triple-Negative Breast Carcinoma
Salubris Biotherapeutics Inc
P1/2
CC
(41)
Lbl-024 For
Triple-Negative Breast Carcinoma
Nanjing Leads Biolabs Co.,Ltd
P1/2
CC
(41)
Mdna11
Triple-Negative Breast Carcinoma
Medicenna Therapeutics, Inc.
P1/2
CC
(41)
Modi-1 Moditope
Triple-Negative Breast Carcinoma
Scancell Ltd
P1/2
CC
(41)
Proagio
Triple-Negative Breast Carcinoma
ProDa BioTech, LLC
P1/2
CC
(41)
Rezatapopt
Triple-Negative Breast Carcinoma
PMV Pharmaceuticals, Inc
P1/2
CC
(41)
sbt6290
Triple-Negative Breast Carcinoma
Silverback Therapeutics
P1/2
CC
(41)
Spedox-6
Triple-Negative Breast Carcinoma
University of California, Irvine
P1/2
CC
(41)
S<sup>3.15</sup>,S<sup>3.22</sup>,S<sup>3.29</sup>-[(1,3,5-triazinane-1,3,5-triyl)tris(3-oxopropane-3,1-diyl)]{N-[5-oxo-5-({L-valyl-N<sup>5</sup>-carbamoyl-L-ornithyl[(4-aminophenyl)methoxy]carbonyl-N-methyl-L-valyl-Lvalyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(2R,3R)-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanamide}-N2.1-yl)pentanoyl]-?-alanyldecakis(N-methylglycyl)-L-alanyl-N6-carbamimidoyl-L-lysyl-L-?-aspartyl-L-cysteinyl-(4R)-4-hydroxy-L-prolyl-L-leucyl-L-valyl-L-asparaginyl-L-prolyl-L-leucyl-L-cysteinyl-L-leucyl-L-histidyl-L-prolyl-D-?-aspartyl-L-tryptophyl-N6-carbamimidoyl-L-lysyl-Lcysteinamide}
Triple-Negative Breast Carcinoma
BicycleTx Limited
P1/2
CC
(41)
tc-510
Triple-Negative Breast Carcinoma
TCR2 Therapeutics
P1/2
CC
(41)
Tetrathiomolybdate
Triple-Negative Breast Carcinoma
Dartmouth-Hitchcock Medical Center
P1/2
CC
(41)
Vls-1488
Triple-Negative Breast Carcinoma
Volastra Therapeutics, Inc.
P1/2
CC
(41)
Hmbd-002
Triple-Negative Breast Carcinoma
Hummingbird Bioscience
P1
CC
(40)
Panobinostat
Triple Negative Breast Cancer
Dana-Farber Cancer Institute
P1
CC
(40)
177lu-dfc413
Triple-Negative Breast Carcinoma
Novartis Pharmaceuticals
P1
C
(37)
[177lu]lu-nns309
Triple-Negative Breast Carcinoma
Novartis Pharmaceuticals
P1
C
(37)
[68Ga]Ga-NNS309
Triple-Negative Breast Carcinoma
Novartis Pharmaceuticals
P1
C
(37)
68Ga-NNS309
Triple-Negative Breast Carcinoma
Novartis Pharmaceuticals
P1
C
(37)
Abbv-400
Triple-Negative Breast Carcinoma
AbbVie
P1
C
(37)
ag-01 compound
Triple-Negative Breast Carcinoma
A&G Pharmaceutical Inc.
P1
C
(37)
Amt-151
Triple-Negative Breast Carcinoma
Multitude Therapeutics Inc.
P1
C
(37)
Anti-Hla-A2/Ny-Eso-1 Tcr-Transduced Autologous T Lymphocytes
Triple Negative Breast Cancer
University of Southern California
P1
C
(37)
Anti-Ny-Eso-1 Tcr Transduced T Cells
Triple-Negative Breast Carcinoma
University of Southern California
P1
C
(37)
ASTX 660
Triple-Negative Breast Carcinoma
Institute of Cancer Research, United Kingdom
P1
C
(37)
Atv-1601
Triple-Negative Breast Carcinoma
Atavistik Bio, Inc
P1
C
(37)
Showing 101 to 125 of 176 assets
Previous
Page 5 of 8
Next
